Form 4: Provectus Biopharmaceuticals CEO Acquires Convertible Note in 2025 Financing

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $25,000, convertible into Series D-1 Preferred Stock, as part of the company's 2025 financing.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), acquired an 8% unsecured convertible promissory note on June 5, 2025.
• The note has a principal value of $25,000 and is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The note will automatically convert into Series D-1 Preferred Stock on June 5, 2026, which is twelve months after its issue date.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless converted earlier.
• The note was issued pursuant to the Issuer's 2025 Financing.
• Following this transaction, Edward Pershing beneficially owns 8,736 shares of Series D-1 Preferred Stock, which are stated to be convertible into 1,960,000 shares of Common Stock, though this figure appears inconsistent with the stated 1:10 conversion ratio for the 8,736 Series D-1 Preferred shares.

Sentiment

Score: 6

Explanation: The acquisition of a convertible note by the CEO indicates insider confidence and provides capital, which is positive. However, the nature of convertible debt and preferred stock implies potential future dilution for common shareholders, and the 8% interest rate is a cost to the company, balancing the sentiment.

Positives

• CEO Edward Pershing's acquisition of a convertible note indicates continued investment and confidence in the company's future prospects.
• The financing structure, involving convertible notes and preferred stock, provides capital to the company for its operations and strategic initiatives.

Negatives

• The issuance of convertible notes and preferred stock can lead to dilution of existing common shareholders upon conversion.
• The 8% interest rate on the unsecured convertible promissory note represents a cost of capital for the company.

Risks

• Potential dilution for existing common shareholders if the convertible note and Series D-1 Preferred Stock are converted into common stock.
• The company's reliance on convertible debt for financing may indicate challenges in securing traditional equity or debt financing on more favorable terms.

Future Outlook

The document indicates future conversions of the acquired convertible note into Series D-1 Preferred Stock by June 5, 2026, and subsequent conversion of Series D-1 Preferred Stock into common stock by June 26, 2026, as part of the company's 2025 financing strategy.

Management Comments

• "The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the 'Note') at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ('Series D-1 Preferred Stock') at a price per share equal to $2.862."
• "The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note."
• "The Note was issued pursuant to the Issuer's 2025 Financing."
• "Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ('Common Stock')."
• "The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock."

Industry Context

This filing reflects a common financing strategy in the biotechnology and pharmaceutical industry, where companies often utilize convertible debt or preferred stock to raise capital, especially for R&D-intensive operations, while managing immediate cash outflows related to interest payments. Such instruments are frequently used by smaller or developing biopharmaceutical firms to fund operations without immediate equity dilution, deferring it until later stages or specific milestones.

Comparison to Industry Standards

• The use of convertible notes and preferred stock is a standard financing mechanism for early to mid-stage biopharmaceutical companies, similar to those employed by firms like XBiotech Inc. (XBIT) or Sorrento Therapeutics (SRNEQ) in their growth phases, which often rely on flexible capital structures to fund clinical trials and product development.
• The 8% interest rate on the unsecured note is within the typical range for unsecured convertible debt issued by smaller biopharmaceutical companies, which often face higher borrowing costs compared to larger, more established pharmaceutical giants like Pfizer (PFE) or Johnson & Johnson (JNJ) due to higher perceived risk and less stable revenue streams.
• The conversion terms, including the 1:10 ratio for preferred to common stock, are specific to the company's capital structure but are generally comparable to other preferred stock issuances in the sector, which aim to balance investor return with potential future dilution.

Related Party Transactions

• The acquisition of an 8% Unsecured Convertible Promissory Note by Edward Pershing, who is both the CEO and a Director of Provectus Biopharmaceuticals, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock due to the conversion of the note and preferred stock into common shares. However, the financing provides capital for company operations, which could benefit long-term value.
• Creditors: The issuance of an unsecured convertible promissory note adds to the company's debt obligations, though it is convertible, potentially reducing future cash interest payments if converted.

Next Steps

• Automatic conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Convertible Preferred Stock on June 5, 2026.
• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 26, 2026.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, SEC Form 4, Insider Transaction, Convertible Note, Series D-1 Preferred Stock, Equity Financing, Dilution, Edward Pershing, Biopharmaceuticals